Trials / Recruiting
RecruitingNCT06682481
Beta-Cell - Liver Interactions in Situations of Modified Beta-Cell Function
Beta-Cell - Liver Interactions in Situations of Modified Beta-Cell Function: From Mice to Children
- Status
- Recruiting
- Phase
- —
- Study type
- Observational
- Enrollment
- 50 (estimated)
- Sponsor
- Philippe Klee, MD-PhD · Academic / Other
- Sex
- All
- Age
- 12 Years – 16 Years
- Healthy volunteers
- Not accepted
Summary
The investigators will measure blood levels of 1,5-anhydroglucitol in obese children with or without type 2 diabetes and correlate them with parameters related to functional beta-cell mass and glucose metabolism. The values will be compared to those obtained in healthy volunteers. The aim of the study is to test the validity of 1,5-anhydroglucitol as a novel biomarker of beta-cell mass and function in children with obesity with or without type 2 diabetes.
Detailed description
One-center prospective study performed in collaboration between the Pediatric Endocrine and Diabetology unit of the University Hospitals of Geneva (HUG) and Prof. Pierre Maechler, Diabetes Center of the Faculty of Medicine, University of Geneva Switzerland. 1,5-anhydroglucitol (1,5-AG), a deoxyhexose present in almost all foods and forming a stable pool in human subjects, has recently been found to be correlated with functional beta-cell mass in two different mouse models of beta-cell dysfunction leading to diabetes. The decline of this biomarker precedes the development of hyperglycemia in lean b-Phb2 -/- and obese db/db diabetic mice, where beta-cell loss occurs through two different mechanisms. Additional studies have shown a correlation of 1,5-AG levels with risk of progression of type 1 diabetes (T1DM) in auto-antibody positive children, as well as with glycaemic control in patients with type 2 diabetes (T2DM). The present project will analyse the correlation between functional beta-cell mass and the circulating levels of 1,5-AG in children with obesity with or without T2DM. This should contribute to the evaluation of a novel biomarker of beta-cell mass and function in T2DM.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| OTHER | Measurement of biomarker | Measurement of blood levels of 1,5-anhydroglucitol |
Timeline
- Start date
- 2024-11-22
- Primary completion
- 2028-12-31
- Completion
- 2028-12-31
- First posted
- 2024-11-12
- Last updated
- 2025-04-02
Locations
1 site across 1 country: Switzerland
Source: ClinicalTrials.gov record NCT06682481. Inclusion in this directory is not an endorsement.